at San Diego, California and other locations
study started
completion around
Principal Investigator
by Praveen Akuthota, MD
Headshot of Praveen Akuthota
Praveen Akuthota



Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.

Official Title

Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis


EGPA, also known as allergic granulomatosis angiitis, is a systemic vasculitis. EGPA is marked by three distinct symptoms: asthma; eosinophilia, evidenced by an excessive number of eosinophils in the blood and tissues; and vasculitis involving the skin, lungs, nerves, kidneys, and other organs. Nerve involvement may also occur in EGPA, causing pain, tingling, numbness, and muscle wasting in the hands and feet. Because EGPA patients may not show any visible signs of active disease, current methods of monitoring disease progression usually represent a period of extended inflammation and disease activity. Thus, patients may go untreated during a period of undetectable disease when damage might be preventable. This study will use novel scientific methods to identify new biomarkers that can be used to monitor disease activity in EGPA patients. These biomarkers may be used to help direct clinical care for EGPA patients and assist in future drug development.

Study visits will occur every 6 months, or annually. Blood and urine collection will occur at every visit. A physical exam and medical and medication history will at every visit; also, participants will be asked to complete several questionnaires to assess disease activity, health status, and tobacco, alcohol, and drug use.


Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome, EGPA, CSS, Granulomatosis with Polyangiitis, Systemic Vasculitis


You can join if…

Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study.

Parent or guardian willing to provide informed consent, if applicable

You CAN'T join if...

- Inability to give informed consent and to sign the consent form


  • University of California San Diego accepting new patients
    San Diego California 92122 United States
  • University of Utah completed
    Salt Lake City Utah 84112 United States
  • National Jewish Health accepting new patients
    Denver Colorado 80206 United States

Lead Scientist at UCSD

  • Praveen Akuthota, MD
    Dr. Akuthota’s research efforts range from basic scientific investigations of human eosinophil biology and eosinophilic inflammation to clinical and translational efforts in asthma and eosinophilic pulmonary disease.


accepting new patients
Start Date
Completion Date
University of Pennsylvania
Vasculitis Clinical Research Consortium Rare Diseases Clinical Research Consortium
Study Type
Expecting 700 study participants
Last Updated